Cargando…
The FDA-Approved Drug Pyrvinium Selectively Targets ER(+) Breast Cancer Cells with High INPP4B Expression
SIMPLE SUMMARY: Wnt/β-catenin signaling is hyperactivated in many human cancers including up to 50% of breast cancers. Although there has been significant progress in developing therapeutics that suppress Wnt/β-catenin signaling, particularly in colon cancer, the repurposing of FDA-approved therapeu...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817693/ https://www.ncbi.nlm.nih.gov/pubmed/36612130 http://dx.doi.org/10.3390/cancers15010135 |